arrow
L

Lauren Nye

The University of Kansas Cancer Center
H指数:13
被引数:867

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Analysis of the Radiosensitivity Index (RSI) in Paired Pre- and Post-Neoadjuvant Therapy Triple-Negative Breast Cancer

配对新辅助治疗前后的三阴性乳腺癌中放射敏感性指数(RSI)的分析

2025-09-250
PRE
Metastatic hormone receptor-positive breast cancer outcomes in 628 patients with BRCA1, BRCA2, or PALB2 pathogenic variants: Real-world data analysis of genomics and targeted therapy sequencing

携带BRCA1、BRCA2或PALB2致病性变异的628例转移性激素受体阳性乳腺癌患者的结局:基因组学和靶向治疗序贯方案的真实世界数据分析

2024-09-010
PRE
SMARCA2 compensation of SMARCA4 loss mediates adaptive resistance to neoadjuvant systemic therapy in triple-negative breast cancer: paired transcriptomic analysis of pre- and post-treatment samples from NeoSTOP and NeoPACT
2024-05-020
PRE
Tumor-Infiltrating Lymphocytes Refine Outcomes in Triple-Negative Breast Cancer Treated with Anthracycline-Free Neoadjuvant Chemotherapy
2024-03-115
OA
Association of TNBC-DX scores with outcomes in triple-negative breast cancer (TNBC) treated with neoadjuvant pembrolizumab and chemotherapy: a correlative analysis from NeoPACT and NeoSTOP trials
2023-03-015
PRE
Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer
2022-07-1131
OAAI
Immunogenicity of SARS-CoV-2 vaccination in subjects on active treatment for breast cancer
2022-02-150
PRE
Clinical and Biomarker Results from Phase I/II Study of PI3K Inhibitor Alpelisib plus Nab-paclitaxel in HER2-Negative Metastatic Breast Cancer

PI3K抑制剂Alpelisib联合Nab-紫杉醇治疗HER2-Negative转移性乳腺癌的I/II期临床和生物标志物结果

2021-02-1844
OA